China (Mainland)
Premiumsupplier 
MGCD0103 CAS NO.726169-73-9
- FOB Price: USD: 1.00-1.00 /Gram Get Latest Price
- Min.Order: 100 Gram
- Payment Terms: L/C
- Available Specifications:
98%(100-500)Gram98%(1000-5000)Gram
- Product Details
Keywords
- MGCD0103
- N-(2-Aminophenyl)-4-([[4-(pyridin-3-yl)pyrimidin-2-yl]amino]methyl)benzamide;MGCD0103;Mocetinostat;MGCD0103(Mocetinostat);MG0103;Mocetinostat (MGCD0103,MG0103);Mocetinostat (MGCD0103);N-(2-Aminophenyl
- 726169-73-9
Quick Details
- ProName: MGCD0103
- CasNo: 726169-73-9
- Molecular Formula: C23H20N6O
- Appearance: White crystal
- Application: CAS：726169-73-9； N-(2-Aminophenyl)-4-...
- DeliveryTime: 3 months
- PackAge: 100g,500g,1kg,25kg
- Port: shang hai
- ProductionCapacity: 1000 Metric Ton/Month
- Purity: 98%
- Storage: Dry seal
- Transportation: shipping
- LimitNum: 100 Gram
Superiority
We are specialized in custom synthesis, chemical/pharmaceutical/ pesticides outsourcing and contract research.
We are committed to provide excellence in researching, manufacturing and drug discovery process.
Our research team of scientists consists of western-trained Ph.D.s with experience and capabilities in drug R&D methodologies and medicinal chemistry.
Details
| Mocetinostat (MGCD0103) 基本信息 |
| 中文名称: | Mocetinostat (MGCD0103) |
| 中文同义词: | N-(2-氨基苯基)-4-([[4-(吡啶-3-基)嘧啶-2-基]氨基]甲基)苯甲酰胺 |
| 英文名称: | Mocetinostat (MGCD0103) |
| 英文同义词: | N-(2-Aminophenyl)-4-([[4-(pyridin-3-yl)pyrimidin-2-yl]amino]methyl)benzamide;MGCD0103;Mocetinostat;MGCD0103(Mocetinostat);MG0103;Mocetinostat (MGCD0103,MG0103);Mocetinostat (MGCD0103);N-(2-Aminophenyl)-4-([[4-(pyridin-3-yl)pyrimidin-2-yl]amino]methyl)benzamide Mocetinostat (MGCD0103) |
| CAS号: | 726169-73-9 |
| 分子式: | C23H20N6O |
| 分子量: | 396.452 |
| EINECS号: | |
| 相关类别: | 信号转导通路激酶抑制剂;Inhibitor;API;小分子抑制剂;Inhibitors;小分子抑制剂，天然产物 |
| Mol文件: | 726169-73-9.mol |
|
|
|
| Mocetinostat (MGCD0103) 性质 |
| Mocetinostat (MGCD0103) 用途与合成方法 |
| 用途 | Mocetinostat is a multi-targeted histone deacetylase inhibitor used in cancer therapy. Mocetinostat is undergoing clinical trials for the treatment of various cancers including follicular lymphoma, Ho dgkin鈥檚 lymphoma and acute myelogenous leukemia. |